TSTickerStarGet alerts

Scinai Immunotherapeutics Reports 167% Revenue Growth for Nine Months Ended September 30, 2026

Scinai Immunotherapeutics reported nine-month 2026 revenue of $2.80 million, a 167% increase year-over-year from $1.05 million, driven by expansion of its CDMO business including the Yavne operations acquired in February 2026. The company reported an operating loss of $6.56 million compared to $5.64 million in the prior-year period, while net loss improved to $0.39 million from $6.24 million primarily due to a $6.40 million noncash bargain purchase gain from the Recipharm Israel acquisition. The company did not...

Share this story

Key takeaways

  • Revenue increased 167% year-over-year to $2.80 million for the nine months ended September 30, 2026, driven by CDMO business expansion including the Yavne operations acquired in February 2026.

  • Operating loss widened to $6.56 million from $5.64 million as revenue growth has not yet offset the enlarged CDMO operating cost base; however, net loss improved to $0.39 million from $6.24 million due to a $6.40 million noncash bargain purchase gain.

  • The company signed an expanded U.S. customer agreement in October with approximately $5.1 million in committed base services, and committed customer orders reached approximately $8.32 million as of November 4, 2026, compared with $1.9 million at year-end 2025.

  • October financing transactions generated approximately $5.3 million in combined net proceeds, bringing reported bank balances to approximately $8.1 million as of October 27, 2026, supporting operating runway to late 2027.

  • The company does not provide formal financial guidance; additional clinical manufacturing in late 2027 and first half of 2028 with indicative value of approximately $5.85 million remains uncommitted and excluded from base commitment.

Key metrics

RevenueNine months ended September 30, 2026
$2.80 million167%
Operating lossNine months ended September 30, 2026
$6.56 million$920 thousand wider loss
Net lossNine months ended September 30, 2026
$0.39 million$5.85 million improvement
Net cash used in operating activitiesNine months ended September 30, 2026
$5.80 million$1.03 million more cash used
Committed Customer OrdersAs of November 4, 2026
$8.32 million330% increase from $1.9 million at year-end 2025

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow SCNI in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert